News

As part of the agreement, Flexion obtained an exclusive license to the underlying intellectual property rights for human use of GQ-203 from Baylor College of Medicine. GQ-203, now

As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S. market without making any upfront payment to

IXIFI is a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor. The drug has now been indicated in the US for the treatment of patients having rheumatoid

The Company’s Board of Directors has unanimously approved the transaction.   Under the terms of the merger agreement, a subsidiary of Allergan will commence a cash tender offer to

The approval has been granted for lyophilized Oncaspar as a component of antineoplastic combination therapy to treat ALL in pediatric patients from birth to 18 years and adult

Harpoon Therapeutics' TriTAC molecules are half-life extended and designed to simultaneously bind to cancer cells and T-cells, triggering those T-cells to attack the targeted cancer cells. These molecules

The late-stage study, dubbed MURANO, demonstrated that Venclexta/Venclyxto, an oral B-cell lymphoma-2 (BCL-2) inhibitor in combination with MabThera/Rituxan cut down the risk of disease progression or death by 83%

Alzheimer’s Clinical Trial Consortium (ACTC), which covers 35 sites across the US, will engage in the development of new and effective ways to treat Alzheimer’s related disorders. The

In connection with the investment, James Peyer, Managing Partner of Apollo Ventures, has joined Aeonian's Board of Directors. Aeonian is an early-stage company engaged in the discovery and